(Yicai) Feb. 6 -- Shares in Guangdong Transtek Medical Electronics soared as much as 9.9 percent today after the Chinese medical device maker said that its blood glucose monitoring system has been given the greenlight to go to market in the US.

Transtek’s share price [SHE:300562] was trading up 5.4 percent at CNY13.74 (USD1.90) as of 1.30 p.m. Earlier in the day it hit CNY14.33.

The TeleRPM Gen2 Blood Glucose Monitoring System, which includes a blood glucose meter and test strips, has recently received approval from the US’ Food and Drug Administration and has completed medical device registration in the country, the Zhongshan-based firm said yesterday.

The blood glucose meter measures the glucose concentration in the blood of adults through external means, it said. Data is then instantly uploaded to a designated server through a 4G connection, allowing patients and doctors to view the test results on their devices. In this way, blood glucose levels can be carefully monitored and controlled.

Being able to sell this product in the US will expand Transtek’s overseas footprint and boost market share, said the firm, which specializes in medical-grade remote health monitoring devices and services. Transtek will actively promote sales of the blood glucose meter going forward, it added.

Overseas sales accounted for 79 percent of Transtek’s annual revenue in 2023, according to its financial report. The firm mainly manufactures home-use medical apparatus and smart wearable devices.

Editor: Kim Taylor